Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1607887 and NEJM ANNEXA-4 Supplement

Webcast ImageWebcast
Q4 2016 Portola Pharmaceuticals, Inc. Earnings Conference Call (Live)
02/28/17 at 1:30 p.m. PT
Q4 2016 Portola Pharmaceuticals, Inc. Earnings Conference Call
Tuesday, February 28, 2017 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Upcoming EventsMore >>
DateTitle
02/28/17 1:30 p.m. PT
Q4 2016 Portola Pharmaceuticals, Inc. Earnings Conference Call
Archived Events
Portola Investor Event During J.P. Morgan Healthcare Conference
Tuesday, January 10, 2017 7:00 a.m. PT
Supporting Materials
Download Event Supporting Material Portola Presentation

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$33.50
Change (%) Stock is Up 1.34 (4.17%)
Volume1,088,967
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
DateTitle 
02/21/17Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and year ended December 31, 2016, and provide a general business overview on Tuesday, February 28, 2017, at 4:30 p.m. ET (1:30 p.m. PT). Conference Call Details The live conference call on Tuesday, February 28, 2017, at 4:30 p.m. Eastern Time, can be accessed by ph... 
Printer Friendly Version
02/08/17FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
PDUFA Date of June 24, 2017 Under Priority Review SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) has informed the Company, as part of its mid-cycle review, that it does not plan to hold an Advisory Committee meeting for Portola’s New Drug Application (NDA) for betrixaban. Betrixaban is an oral, once-daily Factor Xa inhib... 
Printer Friendly Version
02/03/17Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola received $50 million at closing and may receive an additional $100 million upon U.S. Food and Drug Administration (FDA) approval of AndexXaTM (andexanet alfa) in exchange for a tiered, mid-single-digit royalty based on worldwide sales of th... 
Printer Friendly Version
01/03/17Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 10, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. During the investor event, Portola’s senior managemen... 
Printer Friendly Version
12/23/16Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) accepted Portola's New Drug Application (NDA) granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six mo... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.